

Less than 3 weeks to SMI's 3rd Annual Drug Discovery Chemistry Conference

SMi Reports: The countdown begins to the highly anticipated Drug Discovery Chemistry conference in London.

LONDON, GREATER LONDON, UNITED KINGDOM, February 27, 2019 /EINPresswire.com/ -- The drug discovery field is undergoing dramatic change with a new opportunity for the development of [novel medicines and technologies](#) within the pharmaceutical market.

In just 3 weeks, the [Drug Discovery Chemistry conference](#) will open its doors on the 18th and 19th March in London, creating a forum that will discuss the latest innovations in drug discovery chemistry, as well as strategies to deliver small molecules.



The two-day event features 18 thought-provoking presentations, and 4+ hours of networking that will discuss key themes surrounding this ever-changing field of science.

Industry experts will answer these key questions at [Drug Discovery Chemistry 2019](#), including:

1. How arsenic methyl transferase is effective and the potential role in CNS?
AstraZeneca will be discussing the discovery of a form of arsenic methyl transferase (AS3MT).
2. What are the new approaches to drug (chemical biology) the undruggable?
Novartis presents their efforts in chemical biology, exploring new technologies, new modalities and how to win!
3. Are there any advantages of using artificial intelligence in early drug discovery?

Berg LLC, will be discussing the advances in how AI can be used to identify druggable targets and further delve in the opportunities of the drug discovery process.

4. What are the uses and advantages of macrocycles and synthesis for commercial use?

Cylenium Pharma discusses the benefits of macrocycles as an emerging part of chemical space and its potential to drug genomic targets.

5. How is machine learning in drug discovery important?

Bayer will present their findings on machine learning for ADME predications and determining the next steps in the drug discovery process

6. What are the important aspects of fragment-based library design - Ro3 and Beyond?

AbbVie will provide a case study of how the newly designed fragments enabled a fragment to lead campaign in short order.

7. How encoded library technology in nanospheres work?

Nanna Therapeutics will provide an insight into their proprietary screening and AI platform (T.I.M.E.) to speed-up drug discovery, and also provide highlights from their recent case studies. Download the conference brochure with the full two-day agenda and speaker line up at

<http://www.drug-discovery.co.uk/pr5>

The conference has attracted a global audience of experts raring to explore the latest scientific breakthroughs and highlight future opportunities for novel therapeutic discovery.

Register online for the conference and/or post-conference workshop at <http://www.drug-discovery.co.uk/pr5>.

Plus, you can register at the special manager's rate of £999 expiring on Friday 1st March 2019.

Proudly sponsored by Selvita

For sponsorship opportunities please contact Alia Malick, Director on +44 (0) 20 7827 6168 or email amalick@smi-online.co.uk.

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or ssapal@smi-online.co.uk

Drug Discovery Chemistry

Conference: 18th & 19th March 2019

Copthorne Tara Hotel, London, UK

<http://www.drug-discovery.co.uk/pr5>

Follow us @SMiPharm on Twitter

#SMiDrugDischem

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Simi Sapal

SMi Group

+1 2078276000

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/477735062>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.